Form 4: Actinium Pharmaceuticals Director Cancels Stock Options

Sentiment:

SEC Form 4


Director Ajit Shetty cancels multiple stock options in Actinium Pharmaceuticals, effective March 31, 2025, as per an Option Cancellation and Release Agreement.

Summary

  • On April 2, 2025, a Form 4 filing revealed that Ajit Shetty, a director at Actinium Pharmaceuticals, cancelled several stock options.
  • The cancellation, effective March 31, 2025, was made pursuant to an Option Cancellation and Release Agreement between Shetty and Actinium Pharmaceuticals.
  • The cancelled options had various exercise prices and expiration dates, ranging from $4.96 to $47.4 per share.
  • The total number of options cancelled amounted to 174,484 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of an insider transaction (stock option cancellation). It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a broader trend in the pharmaceutical industry.

Stakeholder Impact

  • The cancellation of stock options could have a minor dilutive effect on existing shareholders, although the impact is likely minimal given the relatively small number of shares involved.

Key Dates

DateDescription
03/31/2025Effective date of stock option cancellation.
03/28/2027Expiration date of one of the cancelled stock options.
07/13/2028Expiration date of one of the cancelled stock options.
07/12/2029Expiration date of one of the cancelled stock options.
08/12/2030Expiration date of one of the cancelled stock options.
09/01/2031Expiration date of one of the cancelled stock options.
07/01/2032Expiration date of one of the cancelled stock options.
12/28/2033Expiration date of one of the cancelled stock options.
04/02/2025Date of Form 4 filing.

Keywords

Actinium Pharmaceuticals, Form 4, Stock Options, Ajit Shetty, Director, Cancellation, ATNM

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.